Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients (clinicaltrials.gov) - Jun 16, 2026 - P2 | N=108 | Recruiting | Sponsor: Aspeya, Inc.
New P2 trial • CNS Disorders • Migraine
|